Wolne łańcuchy lekkie

Leave a Comment

Następne cztery posty będą poświęcone głównie wolnym łańcuchom lekkim.  Wszystkie są autorstwa Macieja Korpysza. Ponieważ literatura odnosi się do wszystkich, najpierw umieszczam piśmiennictwo. Później posty.

PIŚMIENNICTWO

 

  1. A.R. Bradwell, H.D. Carr-Smith, G.P. Mead, w wsp: Highly sensitive, automated imunoassay for immunoglobulin free light chains in serum and urine , Clin Chem, 2001, 47, 673–680.
  2. The Binding Site Group. Serum free light chain analysis plus Hevylite, 7h Ed, 2015
  3. Clark SD, Shetty A, Soutar R: Renal failure and multiple myeloma: pathogenesis and treatment of renal failure and management of underlying myeloma. Blood Reviews 1999, 13, 79-90.
  4. Russo L, Bakris GL, Comper WD: Renal handling of albumin: A critical Review of Basic Concepts and Perspective. Am. J. Kidney Dis 2002, 39, 899-919.
  5. Usnarska-Zubkiewicz L., Hołojda J., Kuliczkowski K.: Serum free light chain (sFLC) – diagnostic and prognostic value in plasma cell dyscrasias. Acta Haematol. Pol., 2009, 40, 349.
  6. Katzmann JA, Clark RJ, Abraham RS. i wsp.: Serum reference intervals and diagnostic ranges for free κand free λimmunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem 2002; 48, 1437-1444.
  7. Merlini G, Pozzi C. Mechanisms of renal damage in plasma cell dyscrasias: an overview. Contrib Nephrol 2007;153,66-86.
  8. Rajkumar SV, Dimopoulos MA, Palumbo I wsp.: International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014,15(12),e538-48.
  9. Anna Dmoszyńska, Adam Walter-Croneck, Barbara Pieńkowska-Grela i wsp.: Zalecenia Polskiej Grupy Szpiczakowej dotyczące rozpoznawania i leczenia szpiczaka plazmocytowego oraz innych dyskrazji plazmocytowych na rok 2016. Acta Haematologica Polonica; 2016, 47, 2, 39–85.
  10. Snozek CL, Katzmann JA, Kyle RA i wsp.: Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system. Leukemia, 2008, 22 (10), 1933–1937.
  11. J.A. Katzmann, R.A. Kyle, J. Benson I wsp.: Screening panels for detection of monoclonal gammopathies  Clin Chem, 2009, 55, 1517–1522.
  12. A. Dispenzieri, L. Zhang, J.A. Katzmann i wsp.: Appraisal of immunoglobulin free light chain as a marker of response, Blood, 2008, 111, 4908–4915.
  13. Mead GP, Carr-Smith HD, Drayson MT, Morgan GT, Child JA, Bradwell AR: Serum free light chains for monitoring multiple myeloma. Br. J. Haematol. 2004, 126, 348-354.
  14. Bradwell AR, Carr-Smith HD, Mead GP, Harvey TC, Drayson MT: Serum test for assessment of patients with Bence-Jones myeloma. Lancet 2003, 361, 489-491.
  15. Drayson M, Tang LX, Drew R, Mead GP, Carr-Smith H, Bradwell AR: Serum free light chain measurements for identifying and monitoring patients with non-secretory multiple myeloma. Blood, 2001, 97, 2900-2902.
  16. G.P. Mead, H.D. Carr-Smith, G. Galvin, G. Pratt, A.R. Bradwell: Efficacy of high dose treatment and response to individual chemotherapy agents in myeloma is indicated by changes in serum free light chain concentrations. Clin Chem, 2004, 50, p. C20a
  17. Hassoun H, Reich L, Klimek VM i wsp.: Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma. Br J Haematol 2006,132, 155-161.
  18. Iwama K, Chihara D, Tsuda K I wsp: Normalization of free light chain kappa/lambda ratio is a robust prognostic indicator of favorable outcome in patients with multiple myeloma.Eur J Haematol. 2013,90,134-41.
  19. Yağcı M, Karakaya F, Suyanı E I wsp: Serum free light chain response after 2 courses of induction chemotherapy predicts prognosis in myeloma patients. Clin Lymphoma Myeloma Leuk. 2015,15(2),98-102.
  20. Hansen CT, Pedersen PT, Nielsen LC I wsp: Evaluation of the serum free light chain (sFLC) analysis in prediction of response in symptomatic multiple myeloma patients: rapid profound reduction in involved FLC predicts achievement of VGPR. Eur J Haematol. 2014,93(5),407-13.
  21. Mosbauer, U., Ayuk,  F.,  Schieder i wsp.: Monitoring  serum  free  light  chains  in patients with multiple myeloma who achieved negative immunofixation after allogeneic stem cell transplantation. Haematologica, 2007,92,275–276.
  22. Tang G, Snyder M, Rao LV. Assessement of serum free light chain (FLC) assays with immunofixation electrophoresis (IFE) and bone marrow (BM) immunophenotyping in the diagnosis of plasma cell disorders. Clin Chem 2008; 54: A33: Abstr A-9.
  23. D. Zamarin, S. Giralt, H. Landau i wsp.: Patterns of relapse and progression in multiple myeloma patients after auto-SCT: implications for patients’ monitoring after transplantation Bone Marrow Transplant, 2013, 48, 419–424.
  24. A. Kuhnemund, P. Liebisch, K. Bauchmuller i wsp.: ‘Light-chain escape-multiple myeloma’—an escape phenomenon from plateau phase: report of the largest patient series using LC-monitoring. J Cancer Res Clin Oncol, 2009, 135, 477–484.
  25. Brioli A, Giles H, Pawlyn C i wsp.: Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome. Blood. 2014,123(22), 3414-9.
  26. Rajkumar SV, Lacy MQ, Kyle RA i wsp.: Serum free light chain ratio is an independent risk factor of progression in monoclonal gammopathy of undetermined significance. Blood 2005, 106, 812-817.
  27. Larsen JT, Kumar SK, Dispenzieri A i wsp.: Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma. Leukemia. 2013; 27, 941-6.
  28. Kyrtsonis MC, Vassilakopoulos TP, Kafasi N i wsp.: Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma. Br. J. Haematol., 2007, 137(3), 240–243.
  29. CLH Snozek, JA Katzmann, RA Kyle I wsp.: Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system. Leukemia, 2008, 22, 1933–1937.
  30. Anna Dmoszyńska, Krzysztof Giannopoulos (red.); Szpiczak plazmocytowy I inne dyskrazje plazmocytowe, Wydawnictwo CZELEJ, Lublin 2015.

Dodaj komentarz